Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 7/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 5/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.37 |
| ▸ | LAP3 | P28838 | 4/20 | 0.37 |
| ▸ | ANPEP | P15144 | 2/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20375816 | 1.00 | PAX8 (0.47) | PAX8CAPN1DPP4CTSBCTSK | |
| SCHEMBL20609254 | 1.00 | PAX8 (0.47) | PAX8CAPN1DPP4CTSBCTSK | |
| SCHEMBL3487246 | 0.87 | CAPN1 (0.46) | CAPN1CTSBCTSKSLC7A5ANPEP | |
| SCHEMBL2475740 | 0.87 | CAPN1 (0.46) | CAPN1CTSBCTSKSLC7A5ANPEP | |
| SCHEMBL8817388 | 0.87 | CAPN1 (0.46) | CAPN1CTSBCTSKSLC7A5ANPEP | |
| SCHEMBL16565969 | 0.87 | CAPN1 (0.46) | CAPN1CTSBCTSKSLC7A5ANPEP | |
| SCHEMBL9572309 | 0.87 | CAPN1 (0.46) | CAPN1CTSBCTSKSLC7A5ANPEP | |
| SCHEMBL24324147 | 0.85 | DPP4 (0.46) | PAX8CAPN1DPP4CTSBCTSK | |
| SCHEMBL16980265 | 0.85 | CAPN1 (0.45) | PAX8CAPN1CTSBCTSKSLC7A5 | |
| SCHEMBL5454396 | 0.85 | DPP4 (0.46) | PAX8CAPN1DPP4CTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11466252-B2 | Expansion and differentiation of inner ear supporting cells and methods of use thereof | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2022-10-11 | — | — | US | claimed |
| WO-2025103667-A1 | CLEANING AGENT CONTAINING PROTEASE | HENKEL AG & CO. KGAA (DE) | 2025-05-22 | — | — | WO | disclosed |
| US-11466252-B2 | Expansion and differentiation of inner ear supporting cells and methods of use thereof | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | Frequency Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
| US-20190010449-A1 | Expansion and Differentiation of Inner Ear Supporting Cells and Methods of Use Thereof | MASSACHUSETTS EYE AND EAR INFIRMARY | 2019-01-10 | — | — | US | disclosed |
| EP-0839155-A1 | CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES | PEPTIDE THERAPEUTICS LIMITED (GB) | 1998-05-06 | — | — | EP | disclosed |
| WO-1997004004-A1 | CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES | PEPTIDE THERAPEUTICS LIMITED (GB) | 1997-02-06 | — | — | WO | disclosed |
| EP-0286491-B1 | ANTIMALARIAL AMINOQUINOLINE DERIVATIVES, METHOD FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | LA REGION WALLONNE (BE) | 1992-12-23 | — | — | EP | disclosed |
| EP-0286491-A1 | Antimalarial aminoquinoline derivatives, method for their preparation and pharmaceutical composition containing them | LA REGION WALLONNE (BE) | 1988-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | OTC, EXOSC5, ENTPD5 | PAX8 1436/4885CAPN1 4143/4885DPP4 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.